Human Papillomavirus Lesions in 16 MS Patients Treated with Fingolimod: Outcomes and Vaccination - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue MULTIPLE SCLEROSIS JOURNAL Année : 2021

Human Papillomavirus Lesions in 16 MS Patients Treated with Fingolimod: Outcomes and Vaccination

Résumé

Few cases of human papillomavirus (HPV) diseases have been reported in multiple sclerosis (MS) patients treated with fingolimod. We describe a case series of 16 MS patients (11 women, 5 men) developing HPV lesions after the onset of fingolimod, without previous HPV history. Fingolimod had to be discontinued in six patients. Six patients received vaccination for HPV, with good tolerance. Our report highlights that systematic HPV screening and discussion about HPV vaccination before fingolimod onset are crucial. In case of occurrence of HPV lesions during fingolimod treatment, a comprehensive workup of HPV disease is necessary, with discussion of HPV vaccination to prevent secondary lesions. Prevalence studies of HPV lesions are needed in MS patients with the different disease-modifying therapies.
Fichier non déposé

Dates et versions

hal-03793498 , version 1 (01-10-2022)

Identifiants

Citer

Elsa Mhanna, Agathe Nouchi, Céline Louapre, Raphael de Paz, Olivier Heinzlef, et al.. Human Papillomavirus Lesions in 16 MS Patients Treated with Fingolimod: Outcomes and Vaccination. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (11), pp.1794--1798. ⟨10.1177/1352458521991433⟩. ⟨hal-03793498⟩
38 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More